Evidence map›Paper›PMID 31360022›Full record

ArticleJournal of clinical and experimental hepatology

The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation.

Karen L Thomsen, Francis P Robertson, Peter Holland-Fischer, Brian R Davidson, Rajeshwar P Mookerjee, Holger J Møller, Rajiv Jalan, Henning Grønbæk

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Karen L ThomsenDepartment of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Francis P RobertsonDivision of Surgery and Interventional Science, Royal Free Campus, University College London, United Kingdom.
Peter Holland-FischerLiver Failure Group, UCL Institute for Liver and Digestive Health, University College London, United Kingdom.
Brian R DavidsonDivision of Surgery and Interventional Science, Royal Free Campus, University College London, United Kingdom.
Rajeshwar P MookerjeeLiver Failure Group, UCL Institute for Liver and Digestive Health, University College London, United Kingdom.
Holger J MøllerDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Rajiv JalanLiver Failure Group, UCL Institute for Liver and Digestive Health, University College London, United Kingdom.
Henning GrønbækDepartment of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Aarhus University Hospital · DKUniversity College London · GBThe Royal Free Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesSoluble CD163 (sCD163), a macrophage activation marker, is upregulated in conditions of macrophage proliferation and activation. Elevated sCD163 levels have been associated with liver disease severity and progression. During liver transplantation, the implanted liver is exposed to ischaemia and reperfusion injury, resulting in an acute inflammatory response and macrophage activation. The relationship between sCD163 levels during liver transplantation and the development of early allograft dysfunction (EAD) has not been investigated.

methodsWe included 27 cirrhosis patients (age 55 [range 32-72] years, 23 men) on the waiting list for liver transplantation. Alcohol consumption and viral hepatitis were the most frequent causes for cirrhosis. Patients were characterised by standard biochemical analysis and based on clinical disease severity scores. Information about donor, graft and course of the liver transplantation was recorded. sCD163 levels were measured at the time of liver transplantation before surgery, 2 h after reperfusion, and then at 24 h after transplantation.

resultsWe observed above-normal sCD163 levels at baseline (5.9 mg/L [4.7-8.8]). Two hours after reperfusion, sCD163 levels increased significantly from baseline (8.4 mg/L [7.4-10.9];

conclusionsWe observed elevated sCD163 levels in patients with EAD after liver transplantation, confirming macrophage activation to play a role in EAD. Thus, sCD163 may be used as an early marker for EAD after liver transplantation, but larger studies are warranted to validate these findings.

Indexed as

ALK, alkaline phosphataseALT, alanine aminotransferaseAST, aspartate aminotransferaseBMI, body mass indexCIT, cold ischaemic timeCRP, C-reactive proteinDBD, deceased brain deathDCD, deceased cardiac deathEAD, Early allograft dysfunctionELISA, enzyme-linked immunosorbent assaygraft dysfunctionHb, haemoglobinIL, interleukinINR, international normalised ratioIQR, interquartile rangeI/R, ischaemia/reperfusionliver transplantationmacrophagesMELD, Model for End-Stage Liver DiseaseNAFLD, nonalcoholic fatty liver diseaseNF-κB, nuclear factor- κBPT, prothrombin timesCD163sCD163, soluble CD163TNF-α, tumour necrosis factor αWBC, white blood cellWIT, warm ischaemic time

Identifiers

PMID31360022
PMCPMC6637071
OpenAlexW2895469244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.